67 related articles for article (PubMed ID: 22265862)
21. Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses.
Fan JR; Huang TH; Wen CY; Shen TL; Li TK
Eur J Pharmacol; 2010 Jul; 638(1-3):13-20. PubMed ID: 20406630
[TBL] [Abstract][Full Text] [Related]
22. Transition in survival from low-dose hyper-radiosensitivity to increased radioresistance is independent of activation of ATM Ser1981 activity.
Krueger SA; Collis SJ; Joiner MC; Wilson GD; Marples B
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1262-71. PubMed ID: 17967316
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
25. CGK733 enhances multinucleated cell formation and cytotoxicity induced by taxol in Chk1-deficient HBV-positive hepatocellular carcinoma cells.
Wang H; Zuo B; Wang H; Ren L; Yang P; Zeng M; Duan D; Liu C; Li M
Biochem Biophys Res Commun; 2012 May; 422(1):103-8. PubMed ID: 22564734
[TBL] [Abstract][Full Text] [Related]
26. [Up-regulation of major histocompatibility complex class I-related molecules A (MICA) induced by 5-aza-2'-deoxycytidine].
Wu JF; Zeng GL; Shen W; Yang M; Wang F; Tian L; Li X; Hu WY; Li XP; Ren H; Tang KF
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):675-8. PubMed ID: 19785955
[TBL] [Abstract][Full Text] [Related]
27. Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment.
Cheng CC; Chao WT; Liao CC; Tseng YH; Lai YC; Lai YS; Hsu YH; Liu YH
Cell Adh Migr; 2018 Jan; 12(1):19-27. PubMed ID: 28276928
[TBL] [Abstract][Full Text] [Related]
28. Arginine Depletion plus GCN2 Inhibition Sensitizes HCC Cells to Senolytic Therapies.
Cancer Discov; 2022 Sep; 12(9):2015. PubMed ID: 35866696
[TBL] [Abstract][Full Text] [Related]
29. Show me your signaling--and I'll tell you who you are.
Schattenberg JM; Galle PR
J Hepatol; 2009 Oct; 51(4):638-9. PubMed ID: 19592126
[No Abstract] [Full Text] [Related]
30. Cancer Stem Cell and Hepatic Stellate Cells in Hepatocellular Carcinoma.
Quiroz Reyes AG; Lozano Sepulveda SA; Martinez-Acuña N; Islas JF; Gonzalez PD; Heredia Torres TG; Perez JR; Garza Treviño EN
Technol Cancer Res Treat; 2023; 22():15330338231163677. PubMed ID: 36938618
[TBL] [Abstract][Full Text] [Related]
31. ATM inhibition drives metabolic adaptation via induction of macropinocytosis.
Huang Z; Chen CW; Buj R; Tangudu NK; Fang RS; Leon KE; Dahl ES; Varner EL; von Krusenstiern E; Cole AR; Snyder NW; Aird KM
J Cell Biol; 2023 Jan; 222(1):. PubMed ID: 36399181
[TBL] [Abstract][Full Text] [Related]
32. Caffeine in liver diseases: Pharmacology and toxicology.
Shan L; Wang F; Zhai D; Meng X; Liu J; Lv X
Front Pharmacol; 2022; 13():1030173. PubMed ID: 36324678
[TBL] [Abstract][Full Text] [Related]
33. Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma.
Samadaei M; Senfter D; Madlener S; Uranowska K; Hafner C; Trauner M; Rohr-Udilova N; Pinter M
J Cell Biochem; 2022 Oct; 123(10):1663-1673. PubMed ID: 36271841
[TBL] [Abstract][Full Text] [Related]
34. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib.
Fujii Y; Ono A; Hayes CN; Aikata H; Yamauchi M; Uchikawa S; Kodama K; Teraoka Y; Fujino H; Nakahara T; Murakami E; Miki D; Okamoto W; Kawaoka T; Tsuge M; Imamura M; Chayama K
J Exp Clin Cancer Res; 2021 Jun; 40(1):215. PubMed ID: 34174931
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of ATM and BRCA1 Predicts Poor Outcome in Head and Neck Cancer: Implications for ATM-Targeted Therapy.
Wang YC; Lee KW; Tsai YS; Lu HH; Chen SY; Hsieh HY; Lin CS
J Pers Med; 2021 May; 11(5):. PubMed ID: 34068585
[No Abstract] [Full Text] [Related]
36. Activin a Receptor Type 2A Mutation Affects the Tumor Biology of Microsatellite Instability-High Gastric Cancer.
Yuza K; Nagahashi M; Ichikawa H; Hanyu T; Nakajima M; Shimada Y; Ishikawa T; Sakata J; Takeuchi S; Okuda S; Matsuda Y; Abe M; Sakimura K; Takabe K; Wakai T
J Gastrointest Surg; 2021 Sep; 25(9):2231-2241. PubMed ID: 33420656
[TBL] [Abstract][Full Text] [Related]
37. ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells.
Chen CW; Buj R; Dahl ES; Leon KE; Aird KM
Heliyon; 2020 Sep; 6(9):e05097. PubMed ID: 33024871
[TBL] [Abstract][Full Text] [Related]
38. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma.
Marin JJG; Macias RIR; Monte MJ; Romero MR; Asensio M; Sanchez-Martin A; Cives-Losada C; Temprano AG; Espinosa-Escudero R; Reviejo M; Bohorquez LH; Briz O
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32585893
[TBL] [Abstract][Full Text] [Related]
39. MiR-203a-3p regulates the biological behaviors of ovarian cancer cells through mediating the Akt/GSK-3β/Snail signaling pathway by targeting ATM.
Liu HY; Zhang YY; Zhu BL; Feng FZ; Zhang HT; Yan H; Zhou B
J Ovarian Res; 2019 Jul; 12(1):60. PubMed ID: 31277702
[TBL] [Abstract][Full Text] [Related]
40. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight.
Lohitesh K; Chowdhury R; Mukherjee S
Cancer Cell Int; 2018; 18():44. PubMed ID: 29568237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
